Remove Compound Screening Remove Development Remove FDA Approval Remove Licensing
article thumbnail

Taking a new approach to tackle neurodegenerative diseases

Drug Discovery World

William Erhardt , President, Head of Development & Operations of biotech Oligomerix, tells Lu Rahman about the company’s differentiated approach to developing disease-modifying therapeutics for neurodegenerative diseases. . Overcoming sector challenges .